GlassScriptPhysician profile
Zaher Srour
NPI 1194928069
$4,212.98
in general payments reported to CMS, 2019-2025
29 companies · $1,030 in 2025
The $1,030 reported for 2025 was more than what 77% of Otolaryngic Allergy providers received nationally (typical 2025 total: $449).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $219 · 2021: $598 · 2022: $665 · 2023: $703 · 2024: $543 · 2025: $1,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,907 · Education: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,906.94 |
| Education | $369.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $824.68 | 2019-2025 | Dupixent, Libtayo |
| Optinose US, INC. | $659.58 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $572.01 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $291.43 | 2021-2025 | Nucala |
| Genzyme Corporation | $269.74 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $252.97 | 2023-2025 | |
| Kaleo, INC. | $180.89 | 2019-2022 | |
| Acclarent, INC | $173.65 | 2019-2022 | |
| Intersect Ent, INC. | $154.10 | 2019-2022 | |
| Amgen INC. | $124.92 | 2019-2025 | Tezspire |
| Phathom Pharmaceuticals, INC. | $89.43 | 2024-2025 | Voquezna |
| Stryker Corporation | $81.22 | 2019-2022 | |
| Abbvie INC. | $66.72 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $56.96 | 2022-2024 | |
| Aerin Medical INC. | $50.55 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $38.61 | 2023 | Takhzyro |
| Pfizer INC. | $37.81 | 2023 | |
| Ars Pharmaceuticals Operations, INC. | $36.00 | 2025 | Neffy |
| Medtronic, INC. | $35.37 | 2024 | Propel |
| Aimmune Therapeutics, INC. | $27.80 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $27.67 | 2019-2023 | |
| Neurent Medical Limited | $24.89 | 2022 | |
| Ambu INC. | $23.39 | 2022 | |
| Integra Lifesciences Corporation | $22.84 | 2024 | Acclarent Aera |
| Arrinex, INC. | $20.10 | 2019 | |
| Lilly USA, LLC | $18.42 | 2025 | Zepbound, Mounjaro |
| Paratek Pharmaceuticals, INC. | $18.31 | 2025 | Xhance |
| Merz Pharmaceuticals, LLC | $18.29 | 2025 | Xeomin |
| Alk-Abello, INC | $14.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zaher Srour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.